Nexplanon 68 MG implants
Ended Awarded Last action
- Contract number
- SPE2DR26FJUY1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $16,763
Award facts
- Contract value 100% obligated
- $16,762.60 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $16,762.60 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nexplanon 68 mg implants. Awarded on January 23, 2026, with an ultimate completion date of February 13, 2026, this firm fixed-price delivery order was issued without set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for supplying pharmaceutical products to Department of Defense medical facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance as a critical pharmaceutical supplier within the federal military medical supply chain, with its prime contract under PPV-G GEN V—designated SPE2DR and valued at $499,999,999 through December 31, 2036—authorizing the issuance of firm fixed-price delivery orders for comprehensive pharmaceutical and medical consumables. The company's extensive product portfolio includes branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical devices, positioning it to fulfill the diverse pharmaceutical requirements of Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FJUY1?
SPE2DR26FJUY1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26FJUY1 worth?
The government has obligated $16,763 on SPE2DR26FJUY1.
Is contract SPE2DR26FJUY1 an order under another contract?
Yes. SPE2DR26FJUY1 is a delivery order under SPE2DR25D9329, an indefinite delivery contract.
Was contract SPE2DR26FJUY1 competed?
The extent of competition for SPE2DR26FJUY1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award